Intranasal delivery of MEK Inhibitors to target paediatric gliomas

诺丁汉大学的研究人员一直致力于开发具有赋形剂的新型制剂，旨在增强渗透性，以获得1）通过眼睛治疗后段疾病的新型递送系统，以及2）通过皮肤获得全身递送而无需注射。迄今为止的工作已经确定，可以修改赋形剂的结构，以选择性地增强药物在不同组织中的渗透。所述赋形剂可将>70%的API从局部制剂递送到体内。我们在这个项目中要回答的研究问题是，这项技术是否能通过血脑屏障从鼻腔喷雾中提供治疗药物。这对于儿科患者尤其重要。能够鼻内治疗患有脑癌（如神经胶质瘤）的儿科患者，而不是使用全身给药（患者难以耐受），有可能显着改善患者的健康和药物依从性。它还将在剂量方面提供更大的灵活性。

University of Nottingham researchers have been working on developing novel formulations with excipients designed to enhance penetration to obtain novel delivery systems across 1) the eye to treat diseases in the posterior segment and 2) the skin to obtain systemic delivery without requiring injection. The work so far has determined that it is possible to modify the structure of excipients to selectively enhance the penetration of drugs across different tissues. The excipients can deliver >70% of the API from a topical formulation into the body. The research question we aim to answer in this project is whether this technology will work to deliver therapeutics from a nasal spray across the blood brain barrier. This is key especially for paediatric patients. Having the ability to treat paediatric patients with brain cancers such as gliomas intranasally rather than using systemic delivery (which patients struggle to tolerate) has the potential to significantly improve patient wellbeing and medicine compliance. It would also give greater flexibility around dosing.